03/04/2020 – A letter to our stakeholders on COVID-19 pandemic impact on AB Science clinical studies Post navigationPreviousPrevious post:FDA clears masitinib IND in Amyotrophic Lateral Sclerosis, allowing U.S. patient enrollment to commence in Phase 3 studyNextNext post:2020Related PostsBoursorama interview of Alain Moussy, CEO of AB Science23 December 2020Capital raise for a total amount of 15 million euros21 December 2020Results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease18 December 2020Masitinib in Alzheimer’s Disease Webcast Presentation17 December 2020Results of the Extraordinary General Shareholders’ Meeting of December 16, 202017 December 2020Corrective press release regarding adverse events information from study AB0900417 December 2020